Potential Involvement of Human Leukocyte Antigen-DR/DQ Polymorphisms with Schizophrenia Among Patients with Schizophrenia in Yemen.

Oman Med J

Medical Microbiology and Clinical Immunology Department, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.

Published: January 2024

Objectives: To evaluate the hypothesis that human leukocyte antigens (HLAs) confer susceptibility to schizophrenic disorders, by assessing their contribution to the risk of schizophrenia in a Yemeni population.

Methods: The researchers approached patients who had been diagnosed with schizophrenia at Al-Amal Hospital for Psychiatric Diseases, Sana'a. Controls were drawn randomly from the general population. The HLA class II alleles of the participants were examined. The genotypes of the HLA-DQB1 and HLA-DRB1 alleles were determined by polymerase chain reaction using sequence-specific primers.

Results: The subjects comprised 110 patients with schizophrenia, matched by an equal number of controls. The prevalence of HLA-DRB1*04 was significantly higher among patients than among controls (7.3% vs. 0.0%; 0.003), as was HLA-DRB1*07 (62.7% vs. 17.3%, odds ratio (OR) = 8.1, 95% CI: 4.3-15.1; < 0.001). HLA-DRBI*14 was significantly less prevalent among patients (0.9% vs. 11.8%, OR = 0.06, 95% CI: 0.01-0.50, χ = 10.9; < 0.001). HLA-DQB1*07 was the most common allele discovered in schizophrenia patients and was found to have a much higher incidence in patients than the control group (22.7% vs. 4.5%, OR = 6.2, 95%CI: 2.3-16.8, χ = 15.4; < 0.001).

Conclusions: The HLA-DQB1 and HLA-DRB1 gene loci are linked to schizophrenia in the Yemeni population, according to the current study's evidence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246548PMC
http://dx.doi.org/10.5001/omj.2024.46DOI Listing

Publication Analysis

Top Keywords

human leukocyte
8
schizophrenia patients
8
patients schizophrenia
8
schizophrenia yemeni
8
hla-dqb1 hla-drb1
8
schizophrenia
7
patients
7
potential involvement
4
involvement human
4
leukocyte antigen-dr/dq
4

Similar Publications

Identification of immune characteristics of two lung adenocarcinoma subtypes based on immune- and pyroptosis-related genes to improve immunotherapy.

Bull Cancer

January 2025

Department of Respiratory and Critical Care Medicine, Baoji High-Tech Hospital, Baoji, 721000 Shaanxi, China. Electronic address:

Background: Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer. Pyroptosis is a programmatic cell death linked to inflammation.

Methods: The data information of 541 LUAD samples and 59 normal samples were obtained from TCGA database.

View Article and Find Full Text PDF

Proteomics Analysis of Five Potential Plasma-derived Exosomal Biomarkers for Acute Myocardial Infarction.

Curr Med Chem

January 2025

Department of Cardiology, Taizhou Hospital of Zhejiang Province, affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, China.

Aims: This study was to explore the relationship between plasma exosomes and Acute myocardial infarction (AMI).

Background: Acute myocardial infarction (AMI) is one of the most common cardiovascular complications. Recent studies have shown that exosomes play a crucial role in the development and progression of cardiovascular diseases.

View Article and Find Full Text PDF

Dendritic cells (DCs), the primary antigen-presenting cells, have traditionally been identified by CD103 molecules in rats, whereas mouse and human DCs are identified by CD11c molecules. However, this history does not preclude the existence of CD103 DCs in rats. To explore this possibility, we examined MHCII cells in rat spleen and thymus, identifying a novel population of CD103MHCIICD45RCD172a cells.

View Article and Find Full Text PDF

Background: Antibody-mediated rejection (ABMR) has become one of the leading causes of chronic lung graft dysfunction. However, in lung transplantation, this entity is sometimes difficult and controversial to diagnose. It is mainly caused by the appearance of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA), although there are situations with C4d deposits in biopsy in the absence of circulating DSA.

View Article and Find Full Text PDF

Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy.

Int J Biol Macromol

January 2025

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.

Acute myeloid leukemia (AML) is a severe blood cancer with an urgent need for novel therapies for refractory or relapsed patients. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), an immune suppressive receptor expressed on immune cells and AML blasts but minimally on hematopoietic stem cells (HSCs), represents a potential therapeutic target. But there has been limited research on therapies targeting LAIR1 for AML and no published reports on LAIR1 antibody-drug conjugate (ADC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!